Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.

摘要: Following several randomized trials, neoadjuvant therapy in adenocarcinoma of esophagus and the esophagogastric junction can be seen as an international standard. However, a large proportion patients objective response achieved is unsatisfactory. These do not benefit from therapy, but suffer toxic side effects; sometimes progressive appropriate surgical delayed. For this reason, diagnostic test that accurately assess tumor to might crucial importance. Response evaluation using CT scan, endoluminal ultrasound, or rebiopsy reliable. In recent times, 18FGD PET after during treatment focus clinical scientific interest. Most studies have evaluated modalities for completion treatment. published data so far, FDG-PET seems less accurate chemoradlatlon than chemotherapy alone. The early (14 days onset chemotherapy) are very much encouraging; however, they trial. Standardization technology well defining thresholds used estimation mandatory. So does change esophageal gastric cancer.